aap Implantate AG (OJ:AAQ) Aap Reports Nine-Month Sales Of EUR 24.2 Million (+30%) And EBIT Of Eur 1.3 Million (+16%)

aap Implantate AG (OJ:AAQ) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------



aap Implantate AG, a medical technology company listed on the Frankfurt Stock Exchange in the Prime Standard segment and active in medical biomaterials, fracture healing and joint replacement, achieved a 30% growth in sales in the first nine months of the financial year 2008 to EUR 24.2 million (previous year: EUR 18.6 million). This is based primarily on the disproportionately positive business development of the Traumatology & Orthopaedics (aap T&O) division, where sales growth in the past three quarters has been around 57% higher than last year. The Group operating result rose from EUR 1.1 million to EUR 1.3 million.

+----------------------------------------------------------------+ | In EUR million | Q1-Q3 2008 | Q1-Q3 2007 | Change on Year | |---------------------+------------+------------+----------------| | Sales | 24.2 | 18.6 | + 30% | |---------------------+------------+------------+----------------| | EBITDA | 3.7 | 2.7 | + 35% | |---------------------+------------+------------+----------------| | EBIT | 1.3 | 1.1 | + 16% | |---------------------+------------+------------+----------------| | EBT | 0.6 | 0.8 | - 22% | |---------------------+------------+------------+----------------| | Net period result | 0.4 | 0.2 | + 45% | |---------------------+------------+------------+----------------| | Equity (ratio) | 46.8 (63%) | 42.6 (67%) | + 8% | |---------------------+------------+------------+----------------| | Balance sheet total | 74.0 | 63.7 | + 16% | |---------------------+------------+------------+----------------| | Employees | 302 | 274 | + 10% | +----------------------------------------------------------------+

In the first three quarters of 2008 the Group earned an EBITDA of EUR 3.7 million (previous year: EUR 2.7 million). Group EBIT was EUR 1.3 million (previous year: EUR 1.1 million) and EBT EUR 0.6 million (previous year: EUR 0.8 million). With total assets of EUR 74.0 million (previous year: EUR 63.7 million) the equity ratio after entry of the capital increase in the Commercial Register was 63%.

Highlights of the third Quarter 2008 were the successfully placed 5% capital increase and the signing of an agreement with Zimmer Holdings Inc. on the distribution of the EASYMIX® vacuum mixing system.

For 2008 aap anticipates furthermore an organic sales growth of more than 20%.

The full report on aap Implantate AG's third quarter of 2008 is available for download at www.aap.de. _

aap is a medical technology company that develops, manufactures and markets biomaterials and implants for trauma and orthopaedics. Its product portfolio includes bone cements, bone graft substitutes, antibiotic carriers, and implants for fracture healing and joint replacement. In addition to its Berlin headquarters the company has locations in Dieburg and Obernburg near Frankfurt am Main, Düsseldorf as well as at Nijmegen in the Netherlands. aap Implantate AG has been listed in the Prime Standard segment at the Frankfurt stock exchange since May 16, 2003.

Please address any queries to: aap Implantate AG, Nanette Hüdepohl, Head of Corporate Communications, Lorenzweg 5, 12099 Berlin, Germany Tel.: +49 30 7501 9133; Fax: +49 30 7501 9290; n.huedepohl@aap.de

For further information about aap bio implants, visit www.aap-bioimplants.com

--- End of Message ---

aap Implantate AG Lorenzweg 5 Berlin Germany

WKN: 506660; ISIN: DE0005066609; Index: CDAX, Prime All Share, TECH All Share; Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;

aap Implantate AG

www.aap.de

ISIN: DE0005066609

Stock Identifier: XFRA.AAQ